APRE
Price
$0.89
Change
-$0.01 (-1.11%)
Updated
Jan 15 closing price
Capitalization
6.25M
Intraday BUY SELL Signals
PRQR
Price
$1.58
Change
-$0.06 (-3.66%)
Updated
Jan 15 closing price
Capitalization
166.45M
34 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

APRE vs PRQR

Header iconAPRE vs PRQR Comparison
Open Charts APRE vs PRQRBanner chart's image
Aprea Therapeutics
Price$0.89
Change-$0.01 (-1.11%)
Volume$26.99K
Capitalization6.25M
ProQR Therapeutics
Price$1.58
Change-$0.06 (-3.66%)
Volume$487.31K
Capitalization166.45M
APRE vs PRQR Comparison Chart in %
APRE
Daily Signal:
Gain/Loss:
PRQR
Daily Signal:
Gain/Loss:
View a ticker or compare two or three
VS
APRE vs. PRQR commentary
Jan 16, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is APRE is a Hold and PRQR is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jan 16, 2026
Stock price -- (APRE: $0.89 vs. PRQR: $1.58)
Brand notoriety: APRE and PRQR are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: APRE: 34% vs. PRQR: 90%
Market capitalization -- APRE: $6.25M vs. PRQR: $166.45M
APRE [@Biotechnology] is valued at $6.25M. PRQR’s [@Biotechnology] market capitalization is $166.45M. The market cap for tickers in the [@Biotechnology] industry ranges from $111.36B to $0. The average market capitalization across the [@Biotechnology] industry is $2.26B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

APRE’s FA Score shows that 2 FA rating(s) are green whilePRQR’s FA Score has 1 green FA rating(s).

  • APRE’s FA Score: 2 green, 3 red.
  • PRQR’s FA Score: 1 green, 4 red.
According to our system of comparison, APRE is a better buy in the long-term than PRQR.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

APRE’s TA Score shows that 6 TA indicator(s) are bullish while PRQR’s TA Score has 4 bullish TA indicator(s).

  • APRE’s TA Score: 6 bullish, 2 bearish.
  • PRQR’s TA Score: 4 bullish, 5 bearish.
According to our system of comparison, APRE is a better buy in the short-term than PRQR.

Price Growth

APRE (@Biotechnology) experienced а -4.90% price change this week, while PRQR (@Biotechnology) price change was -24.76% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +0.72%. For the same industry, the average monthly price growth was +2.38%, and the average quarterly price growth was +41.99%.

Reported Earning Dates

PRQR is expected to report earnings on Feb 19, 2026.

Industries' Descriptions

@Biotechnology (+0.72% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
PRQR($166M) has a higher market cap than APRE($6.25M). APRE YTD gains are higher at: 4.807 vs. PRQR (-21.782). APRE has higher annual earnings (EBITDA): -13.8M vs. PRQR (-38.15M). PRQR has more cash in the bank: 107M vs. APRE (13.7M). APRE has less debt than PRQR: APRE (0) vs PRQR (16.5M). PRQR has higher revenues than APRE: PRQR (15.5M) vs APRE (0).
APREPRQRAPRE / PRQR
Capitalization6.25M166M4%
EBITDA-13.8M-38.15M36%
Gain YTD4.807-21.782-22%
P/E RatioN/AN/A-
Revenue015.5M-
Total Cash13.7M107M13%
Total Debt016.5M-
FUNDAMENTALS RATINGS
APRE vs PRQR: Fundamental Ratings
APRE
PRQR
OUTLOOK RATING
1..100
558
VALUATION
overvalued / fair valued / undervalued
1..100
13
Undervalued
25
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9899
PRICE GROWTH RATING
1..100
8990
P/E GROWTH RATING
1..100
4100
SEASONALITY SCORE
1..100
5085

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

APRE's Valuation (13) in the null industry is in the same range as PRQR (25) in the Biotechnology industry. This means that APRE’s stock grew similarly to PRQR’s over the last 12 months.

APRE's Profit vs Risk Rating (100) in the null industry is in the same range as PRQR (100) in the Biotechnology industry. This means that APRE’s stock grew similarly to PRQR’s over the last 12 months.

APRE's SMR Rating (98) in the null industry is in the same range as PRQR (99) in the Biotechnology industry. This means that APRE’s stock grew similarly to PRQR’s over the last 12 months.

APRE's Price Growth Rating (89) in the null industry is in the same range as PRQR (90) in the Biotechnology industry. This means that APRE’s stock grew similarly to PRQR’s over the last 12 months.

APRE's P/E Growth Rating (4) in the null industry is significantly better than the same rating for PRQR (100) in the Biotechnology industry. This means that APRE’s stock grew significantly faster than PRQR’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
APREPRQR
RSI
ODDS (%)
Bullish Trend 3 days ago
74%
Bullish Trend 3 days ago
87%
Stochastic
ODDS (%)
Bullish Trend 3 days ago
78%
Bullish Trend 3 days ago
85%
Momentum
ODDS (%)
Bullish Trend 3 days ago
69%
Bearish Trend 3 days ago
86%
MACD
ODDS (%)
Bullish Trend 3 days ago
85%
Bearish Trend 3 days ago
85%
TrendWeek
ODDS (%)
Bullish Trend 3 days ago
78%
Bearish Trend 3 days ago
84%
TrendMonth
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 3 days ago
83%
Advances
ODDS (%)
Bullish Trend 8 days ago
77%
Bullish Trend 10 days ago
84%
Declines
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 4 days ago
84%
BollingerBands
ODDS (%)
Bullish Trend 3 days ago
86%
Bullish Trend 3 days ago
90%
Aroon
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 3 days ago
86%
View a ticker or compare two or three
Interact to see
Advertisement
APRE
Daily Signal:
Gain/Loss:
PRQR
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
TCRT2.810.07
+2.55%
Alaunos Therapeutics Inc.
MANU16.900.31
+1.87%
Manchester United PLC
ALRS24.150.17
+0.71%
Alerus Financial Corp
TWLO119.78-3.25
-2.64%
Twilio
SSTI8.04-0.52
-6.07%
SoundThinking

APRE and

Correlation & Price change

A.I.dvisor tells us that APRE and ATOS have been poorly correlated (+32% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that APRE and ATOS's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To APRE
1D Price
Change %
APRE100%
-0.67%
ATOS - APRE
32%
Poorly correlated
-3.64%
CRBU - APRE
31%
Poorly correlated
-3.11%
EYPT - APRE
29%
Poorly correlated
-0.50%
TBPH - APRE
29%
Poorly correlated
-2.43%
PRQR - APRE
28%
Poorly correlated
-3.66%
More

PRQR and

Correlation & Price change

A.I.dvisor indicates that over the last year, PRQR has been loosely correlated with RGNX. These tickers have moved in lockstep 49% of the time. This A.I.-generated data suggests there is some statistical probability that if PRQR jumps, then RGNX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PRQR
1D Price
Change %
PRQR100%
-3.66%
RGNX - PRQR
49%
Loosely correlated
-7.96%
BEAM - PRQR
46%
Loosely correlated
-9.49%
RNAC - PRQR
44%
Loosely correlated
-3.66%
ETHZ - PRQR
44%
Loosely correlated
+0.18%
DNLI - PRQR
44%
Loosely correlated
+2.79%
More